Phase II RCT in 281 UK adolescents aged 12-15 given a third COVID-19 dose: 10 μg adult-formulation BNT162b2 was non-inferior and superior to 10 μg paediatric BNT162b2 for anti-spike IgG at day 28 (aGMR 1.50); reactions were mostly mild to moderate.
Clinical trialn = 281
Kelly et al. Reactogenicity and immunogenicity following heterologous and homologous third dose COVID-19 vaccination in UK adolescents (Com-COV3): A randomised controlled non-inferiority trial